Addressing Suboptimal Anti-VEGF Response in Neovascular AMD and DME : Episode 1

Addressing Suboptimal Anti-VEGF Response in Neovascular AMD and Diabetic Macular Edema

July 10, 2024

By Hong-Uyen Hua, MD
Sruthi Arepalli, MD

Opinion

Video

A panel of ophthalmologists discuss strategies for managing AMD and DME patients who exhibit suboptimal responses to their current anti-VEGF therapy.

EP: 1.Addressing Suboptimal Anti-VEGF Response in Neovascular AMD and Diabetic Macular Edema

1:00 Suboptimal Response
6:30 Treatment Strategy
11:10 Response to New Therapies
14:00 Imaging for Monitoring
18:30 Role of Ang-2

Recent Videos

3 KOLs are featured in this series.

Dennis M. Marcus, MD , an expert on neovascular AMD

A panel of 3 experts on dry eye

Psoriasis podcast

A panel of 3 experts on RVO

Dennis M. Marcus, MD , an expert on neovascular AMD

HCPLive Five at ASRS 2024 | Image Credit: HCPLive

Jordana Fein, MD: Pre-Dose IOP Outcomes After Aflibercept 8 mg for DME | Image Credit: LinkedIn

Diana Do, MD: Impact of Baseline BCVA on Aflibercept 8 mg Outcomes in DME | Image Credit: Stanford University

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.